Statistical analysis of influenza vaccine lot consistency studies

Journal of Biopharmaceutical Statistics

Volumn 16, Issue 4, 2006, Pages 443-452

  Nauta, J ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Equivalence margin; Immunogenicity; Influenza vaccines; Lot consistency; Statistical analysis

Indexed keywords

INFLUENZA VACCINE; VIRUS HEMAGGLUTININ;

ANALYTICAL ERROR; ANTIBODY TITER; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA; PRIORITY JOURNAL; PROBABILITY; QUESTIONNAIRE; STATISTICAL ANALYSIS; VACCINE PRODUCTION; VIRUS STRAIN;

DOUBLE-BLIND METHOD; DRUG INDUSTRY; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; RANDOMIZED CONTROLLED TRIALS;

EID: 33745726453     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400600719277     Document Type: Article

References (17)

1. Armitage, P., Berry, G. (1994). Statistical Methods in Medical Research. 3rd ed. Blackwell Science, pp. 128-130.
2. Berger, R. L. (1982). Multiparameter hypothesis testing and acceptance sampling. Technometrics 24:295-300.
3. Berger, R. L., Hsu, J. C. (1996). Bioequivalence trials, intersection-union tests and equivalence confidence sets. Statistical Sciences 11:283-319.
4. Beyer, W. E. P., Palache, A. M., Lüchters, G., Nauta, J., Osterhaus, A. D. M. E. (2004). Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res. 103:125-132.
5. De Jong, J. C., Palache, A. M., Beyer, W. E. P., Rimmelzman, G. F., Boon, A. C. M., Osterhaus, A. D. M. E. (2003). Haemagglutination-inhibiting antibody to influenza virus. Dev. Biol. 115:63-73.
6. Dowdle, W. E., Kendal, A., Noble, W. R. (1979). Influenza Viruses. In: Lennette, E. H., Schmidt, N. J., eds. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. 5th ed. Washington DC: American Public Health Association.
7. Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing, and Clinical Studies. (1997). U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.
8. Lachenbruch, P. A., Rida, W., Kou, J. (2004). Lot consistency as an equivalence problem. J. Biopharm. Stat. 14:275-290.
9. Nolan, T., Lee, M. S., Cordova, J. M., Cho, I., Walker, R. E., August, M. J., Larson, S., Coelingh, K. L., Mendelman, P. M. (2003). Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 21:1224-1231.
10. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. (1997). Committee for Proprietary Medicinal Products (CPMP). CPMP/BWP/214/96.
11. Note for Guidance on Clinical Evaluation of New Vaccines. Committee for Proprietary Medicinal Products (CPMP). (1999). CPMP/EWP/463/97.
12. Schuirmann, D. (1987). A comparison of the two one-sided tests procedure and the power for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15:657-80.
13. Statistical Principles for Clinical Trials. (1998). International Conference on Harmonization (ICH) E9 Expert Working Group.
14. Wiens, B. L., Iglewicz, B. (1999). On testing equivalence of three populations. J. Biopharm. Stat. 9:465-483.
15. Wiens, B. L., Iglewicz, B. (2000). Design and analysis of three treatment equivalence trials. Control. Clin. Trials 21:127-137.
16. Wiens, B. L. (2002). Choosing an equivalence limit for noninferiority or equivalence studies. Control. Clin. Trials 23:2-14.
17. Zangwill, K. M., Droge, J., Mendelman, P., Marcy, M., Partridge, S., Chiu, C. Y., Jing, J., Chang, S. J., Cho, I., Ward, J. I. (2001). Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. J. Pediatr. Infect. Dis. 20:740-746.